Publication:
A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients FINE Trial

dc.contributor.authorsAkman Demir, Gulsen; Turkoglu, Recai; Saip, Sabahattin; Yuceyar, Nur; Efendi, Husnu; Turan, Omer Faruk; Agan, Kadriye; Terzi, Murat; Boz, Cavit; Tuncer, Asli; Kocer, Belgin; Kasap, Mithat; Caliskan, Zeynep
dc.date.accessioned2022-03-14T10:04:47Z
dc.date.available2022-03-14T10:04:47Z
dc.date.issued2017-06-20
dc.description.abstractIntroduction: To assess satisfaction and quality of life in patients with relapsing-remitting multiple sclerosis (RRMS) who were receiving fingolimod (0.5 mg/day) for 12 months as a second-line treatment after switching from injectable agents. Methods: Patients aged 18-65 years with RRMS who fulfilled the eligibility criteria were enrolled from 16 centers throughout Turkey. Treatment Satisfaction Questionnaire for Medication and 36-item Short-Form Health Survey were completed at baseline and four visits to assess patient satisfaction and quality of life. Results: Forty-two patients (62% male; mean age: 35.7 +/- 9.4 years) were eligible for inclusion. Patient satisfaction scores at the end of the study 44.7 +/- 9.9) were significantly higher than those at baseline [32.0 +/- 9.9; (p<0.001)]. The only significant increase in the quality of life survey was in the emotional aspect (p=0.019). There were 124 adverse events and none of the five serious adverse events noted was considered drugrelated. Conclusion: Large-scale comparative studies performed with disease specific quality of life instruments will allow more information on this issue.
dc.identifier.doi10.5152/npa.2017.20515
dc.identifier.eissn1309-4866
dc.identifier.issn1300-0667
dc.identifier.pubmed31903032
dc.identifier.urihttps://hdl.handle.net/11424/244015
dc.identifier.wosWOS:000510207600005
dc.language.isoeng
dc.publisherAVES
dc.relation.ispartofNOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectMultiple sclerosis
dc.subjectfingolimod
dc.subjectpatient satisfaction
dc.subjectquality of life
dc.subjectORAL FINGOLIMOD
dc.subjectINTRAMUSCULAR INTERFERON
dc.subjectDOUBLE-BLIND
dc.subjectSAFETY
dc.subjectTHERAPIES
dc.subjectEFFICACY
dc.subjectOUTCOMES
dc.subjectACETATE
dc.subjectPHASE-3
dc.subjectSWITCH
dc.titleA 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients FINE Trial
dc.typearticle
dspace.entity.typePublication
local.import.packageSS16
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.indexed.atTRDIZIN
local.journal.numberofpages5
local.journal.quartileQ4
oaire.citation.endPage257
oaire.citation.issue4
oaire.citation.startPage253
oaire.citation.titleNOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY
oaire.citation.volume56

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Akman Demir et al. - 2017 - A 12-month, Open Label, Multicenter Pilot Study Ev.pdf
Size:
101.34 KB
Format:
Adobe Portable Document Format

Collections